Potential pitfalls of 18F-FDG PET in a large series of patients treated for malignant lymphoma: prevalence and scan interpretation
- 1 August 2005
- journal article
- research article
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 26 (8) , 689-694
- https://doi.org/10.1097/01.mnm.0000171781.11027.bb
Abstract
To evaluate the prevalence and scan interpretation criteria useful in identifying non-tumoural 18F-FDG focal uptakes (potential pitfalls) in patients who had been previously treated for a malignant lymphoma studied by positron emission tomography (PET). Nine hundred and ninety-six consecutive PET scans obtained in 706 patients with malignant lymphoma were reviewed. All patients had been previously treated by first-line chemo-radiotherapy, plus surgery when required, and were then studied by FDG PET to investigate suspected recurrence at doubtful or inconclusive conventional radiological imaging (ultrasound, computed tomography, magnetic resonance imaging). PET was obtained with patients in the fasted condition and after i.v. injection of 370 MBq of 18F-FDG; imaging was acquired 60–90 min later. In patients with focal FDG uptake the final diagnosis was reached on the basis of histological findings or long-term follow-up. Thirty-one of 134 PET scans (23.1%) showing focal FDG uptake were diagnosed as non-tumoural radiotracer uptake, related to the presence of brown fat in seven cases, thymic hyperplasia in five, muscles contraction in four, lymph node unspecific inflammation in four, mediastinal/pulmonary unspecific inflammation in four, gastritis in two, colitis in two, bacterial abscess in one, lactating breast in one, and herpes zoster in one. Each of the above cited situations has been reported in the literature, generally in the form of sporadic reports, as a potential cause of misinterpretation (false positive) in reading a PET scan with the potential for incorrect patient management. An accurate diagnosis in these patients was important for the following therapeutic decision making. In the whole series of patients with treated malignant lymphoma, the prevalence of non-tumoural FDG focal uptake during follow-up was relatively low (3.1%); conversely, it was relatively high when considering the sub-group of ‘positive’ PET only (23.1%). The importance of knowing these situations in order to avoid misinterpretation in reading PET scans needs to be emphasized. In this light, an accurate patient's history and a skilful nuclear medicine physician are very important factors. For the same purpose, it is reasonable to think that the use of hybrid PET/CT tomographs could also play an important role in helping to identify non-tumoural FDG focal uptake.Keywords
This publication has 16 references indexed in Scilit:
- FDG PET in the follow-up management of patients with newly diagnosed Hodgkin and non-Hodgkin lymphoma after first-line chemotherapyInternational Journal of Radiation Oncology*Biology*Physics, 2003
- Limitations of PET for imaging lymphomaEuropean Journal of Nuclear Medicine and Molecular Imaging, 2003
- Positron emission tomography in the management of lymphomas: a summaryEuropean Journal of Nuclear Medicine and Molecular Imaging, 2003
- PET in lymphoma: what are the oncologist's needs?European Journal of Nuclear Medicine and Molecular Imaging, 2003
- Early restaging positron emission tomography with 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin’s lymphomaAnnals of Oncology, 2002
- 2-Deoxy-2-[F-18]Fluoro-D-Glucose Imaging with Positron Emission Tomography for Initial Staging of Hodgkin's Disease and LymphomaMolecular Imaging & Biology, 2002
- Thoracic positron emission tomography using18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin diseaseBlood, 2001
- Can positron emission tomography with [18F]‐fluorodeoxyglucose after first‐line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?British Journal of Haematology, 2001
- Fluorine-18 fluorodeoxyglucose positron emission tomography in the staging and follow-up of lymphoma: is it time to shift gears?European Journal of Nuclear Medicine and Molecular Imaging, 2000
- Positron Emission Tomography in Diagnosis and Therapy Monitoring of Patients with LymphomaClinical Positron Imaging, 1998